Financiado en parte por GlaxoSmithKline
Strong Relation Between Muscle Mass Determined by D3-creatine Dilution, Physical Performance, and Incidence of Falls and Mobility Limitations in a Prospective Cohort of Older Men
Cawthon PM, Orwoll ES, Peters KE, Ensrud KE, Cauley JA, Kado DM, Stefanick ML, Shikany JM, Strotmeyer ES, Glynn NW, Caserotti P, Shankaran M, Hellerstein M, Cummings SR, Evans WJ, Osteoporotic Fractures in Men (MrOS) Study Research Group
The journals of gerontology. Series A, Biological sciences and medical sciences · 184 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- GlaxoSmithKline
- Gobierno
- National Institutes of Health
- Gobierno
- National Institute on Aging
- Gobierno
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- NIAMS NIH HHS
- Gobierno
- NIH Roadmap for Medical Research
- Gobierno
- NIA NIH HHS
- Gobierno
- NCATS NIH HHS
- Subvenciones
- National Institute on Aging (U01AG042168); National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01 AG042145); National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01 AG042140); National Institute on Aging (UL1TR000128); National Center for Advancing Translational Sciences (UL1TR000128); National Institute on Aging (AG042140); National Center for Advancing Translational Sciences (U01 AG042124); National Center for Advancing Translational Sciences (U01 AG042168); National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01 AG042143); National Institute on Aging (AG042139); National Institute on Aging (U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160); National Center for Advancing Translational Sciences (U01AG042145); National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01 AG027810); National Institute of Arthritis and Musculoskeletal and Skin Diseases (UL1 TR000128); National Institute on Aging (AG042168); National Institute on Aging (U01 AG042124); National Center for Advancing Translational Sciences (U01 AG042139); National Institute on Aging (AG042124); National Center for Advancing Translational Sciences (R01 AR065268); National Institute on Aging (AG042145); National Center for Advancing Translational Sciences (U01 AG-042140); National Institute on Aging (U01 AR066160); National Center for Advancing Translational Sciences (U01 AR066160); National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01 AR066160); National Center for Advancing Translational Sciences (U01 AG042143); National Institute on Aging (U01AG042139); National Institute on Aging ((P30AG024827); National Institute on Aging (U01 AG-042140); National Institute on Aging (U01 AG027810); National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01 AG042139); National Center for Advancing Translational Sciences (TR000128); National Institute on Aging (AG027810); National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01 AG042124); National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR066160); National Institute on Aging (R01 AR065268); National Center for Advancing Translational Sciences (U01 AG027810); National Institute on Aging (U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128); National Institute on Aging (AG042143); National Institute on Aging (U01AG042145); National Institute on Aging (U01 AG042143); National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR065268); National Institutes of Health (AG042168); National Institutes of Health (AG042139); National Institutes of Health (U01 AG042124); National Institutes of Health (AR066160); National Institutes of Health (UL1TR000128); National Institutes of Health (U01 AG042168); National Institutes of Health (AG042140); National Institutes of Health (U01-AG027810); National Institutes of Health (U01 AG042139); National Institutes of Health (U01 AG042145); National Institutes of Health (AG027810); National Institutes of Health (TR000128); National Institutes of Health (U01AR066160); National Institutes of Health (U01 AG042143); National Institutes of Health (AG042124); National Institutes of Health (U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128.); National Institutes of Health (AG042143); National Institutes of Health (U01 AG042140); National Institutes of Health (AG042145); National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01 AG042168)
Según 9 financiadores declarados.
Publicación
- Publicado
- 2018-06-12 · J Gerontol A Biol Sci Med Sci · vol. 74 · número 6 · págs. 844–852
- Editorial
- Oxford University Press
- Citado
- 218 citas · más que el 99% de estudios similares · 11.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 40 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Nutrition and Health in Aging · Balance, Gait, and Falls Prevention · Frailty in Older Adults
- Palabras clave
- Creatine, Incidence (geometry), Prospective cohort study, Cohort, Medicine, Gerontology, Falls in older adults, Physical medicine and rehabilitation, Environmental health, Physiology, Psychology, Demography, Internal medicine, Injury prevention, Poison control, Mathematics
- MeSH
- muscle, skeletal, humans, deuterium, creatine, absorptiometry, photon, body mass index, hand strength, multivariate analysis, cohort studies, indicator dilution techniques, accidental falls, aged, 80 and over, male, mobility limitation, walking speed, physical functional performance
15 autores
- Peggy Mannen Cawthon🇺🇸 · autor de correspondenciaUniversity of California, San Francisco; California Pacific Medical Center
- ERIC S. ORWOLL🇺🇸Oregon Health & Science University
- Katherine E. Peters🇺🇸 · autor de correspondenciaCalifornia Pacific Medical Center
- Kristine E. Ensrud🇺🇸University of Minnesota; Minneapolis VA Health Care System
- Jane A. Cauley🇺🇸University of Pittsburgh
- Deborah M. Kado🇺🇸University of California San Diego
- Marcia L. Stefanick🇺🇸Stanford University
- James M. Shikany🇺🇸University of Alabama at Birmingham
- Elsa S. Strotmeyer🇺🇸University of Pittsburgh
- Nancy W. Glynn🇺🇸University of Pittsburgh
- Paolo Caserotti🇩🇰University of Southern Denmark
- Mahalakshmi Shankaran🇺🇸University of California, Berkeley
- Marc K. Hellerstein🇺🇸University of California, San Francisco; University of California, Berkeley
- Steven Ron Cummings🇺🇸University of California, San Francisco; California Pacific Medical Center
- William J. Evans🇺🇸Duke University; University of California, Berkeley
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Direct assessment of skeletal muscle mass in older adults is clinically challenging. Relationships between lean mass and late-life outcomes have been inconsistent. The D3-creatine dilution method provides a direct assessment of muscle mass.
Methods
Muscle mass was assessed by D3-creatine (D3Cr) dilution in 1,382 men (mean age, 84.2 years). Participants completed the Short Physical Performance Battery (SPPB); usual walking speed (6 m); and dual x-ray absorptiometry (DXA) lean mass. Men self-reported mobility limitations (difficulty walking 2-3 blocks or climbing 10 steps); recurrent falls (2+); and serious injurious falls in the subsequent year. Across quartiles of D3Cr muscle mass/body mass, multivariate linear models calculated means for SPPB and gait speed; multivariate logistic models calculated odds ratios for incident mobility limitations or falls.
Results
Compared to men in the highest quartile, those in the lowest quartile of D3Cr muscle mass/body mass had slower gait speed (Q1: 1.04 vs Q4: 1.17 m/s); lower SPPB (Q1: 8.4 vs Q4: 10.4 points); greater likelihood of incident serious injurious falls (odds ratio [OR] Q1 vs Q4: 2.49, 95% confidence interval [CI]: 1.37, 4.54); prevalent mobility limitation (OR Q1 vs Q4,: 6.1, 95% CI: 3.7, 10.3) and incident mobility limitation (OR Q1 vs Q4: 2.15 95% CI: 1.42, 3.26); p for trend < .001 for all. Results for incident recurrent falls were in the similar direction (p = .156). DXA lean mass had weaker associations with the outcomes.
Conclusions
Unlike DXA lean mass, low D3Cr muscle mass/body mass is strongly related to physical performance, mobility, and incident injurious falls in older men.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.